Table 2.

Infection events according to last ALC prior to infection event.

	Placebo QD [N = 260]	Etrasimod 2 mg QD [N = 527]
Minimum ALC at any time post-baseline; n [%]	254 [97.69]	519 [98.48]
ALC < 0.2 × 109/L; n [%]a	0 [0.0]	18 [3.5]
Serious/severe infections; n	0	0
Opportunistic infections; n	0	0
Herpes zoster; n	0	0
Infections leading to discontinuation; n	0	0
ALC < 0.5 × 109/L; n [%]a	5 [2.0]	206 [39.7]
Serious/severe infections; n	0	1
Opportunistic infections; n	0	0
Herpes zoster; n	0	1
Infections leading to discontinuation; n	0	0
ALC ≥ 0.5 × 109/L; n [%]a	249 [98.0]	295 [56.8]
Serious/severe infections; n	5	2
Opportunistic infections; n	1	1
Herpes zoster; n	2	1
Infections leading to discontinuation; n	1	2

ALC, absolute lymphocyte count; N, number of patients in the Pivotal UC cohort; n, number of patients with evaluable data; QD, once daily.

^aPercentages are based on the number of patients with minimum ALC readings at any time post-baseline.